I had a board member on here ask a question about
Post# of 30066
(Total Views: 381)
Posted On: 02/08/2020 3:08:55 AM
.jpg)
I had a board member on here ask a question about this new effort with $DYAI. Wanted to share my thoughts for all:
If you just follow the # of preclinical and academic publications in semantic scholar you saw interest and research on MANF go exponential a few years ago. Even if you didn't read them, you would guess there's a probability a certain number trickle down to additional study and development. But if you did read them and start to connect the dots on authors, you would start to see the momentum building. The CDNF results are win/win for us because we're still the best bet according to preclinical. The fact that so many participants finished the study and signed on for an extension is a huge de-risking event for human MANF studies. It's unclear whether attempting to up the manufacturing sophistication is in preparation for a particular line of effort, or the general sense of opportunity, or being approached for multiple development opportunities in the market and academia, but it's a clear signal of the company trajectory, and yet another player, a NASDAQ biotech of some sophistication who took a look at us and wanted to be a part of things.
If you just follow the # of preclinical and academic publications in semantic scholar you saw interest and research on MANF go exponential a few years ago. Even if you didn't read them, you would guess there's a probability a certain number trickle down to additional study and development. But if you did read them and start to connect the dots on authors, you would start to see the momentum building. The CDNF results are win/win for us because we're still the best bet according to preclinical. The fact that so many participants finished the study and signed on for an extension is a huge de-risking event for human MANF studies. It's unclear whether attempting to up the manufacturing sophistication is in preparation for a particular line of effort, or the general sense of opportunity, or being approached for multiple development opportunities in the market and academia, but it's a clear signal of the company trajectory, and yet another player, a NASDAQ biotech of some sophistication who took a look at us and wanted to be a part of things.
(2)
(0)